12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Aeterna Zentaris preclinical data

In mice, single and multiple doses of oral AEZS-120 each led to significant and comparable protection from challenge with a recombinant prostate-specific antigen (

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >